ストックスクリーナーアプリを入手
6.12
17.63%
-1.31
アフターアワーズ：
6.15
0.03
+0.49%
前日終値:
$7.43
開ける：
$7.15
24時間の取引高:
3.43M
Relative Volume:
2.10
時価総額：
$361.67M
収益：
$192.64M
当期純損益:
$2.51M
株価収益率:
116.79
EPS:
0.0524
ネットキャッシュフロー:
$12.42M
1週間 パフォーマンス:
-15.35%
1か月 パフォーマンス:
-17.41%
6か月 パフォーマンス:
+42.00%
1年 パフォーマンス:
+28.84%
1日の値動き範囲:
$6.005
$7.15
1週間の範囲:
$6.005
$7.72
52週間の値動き範囲:
$3.8092
$9.60
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
名前
Vanda Pharmaceuticals Inc
セクター
電話
202-734-3400
住所
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
6.12 | 439.09M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-05 | 開始されました | B. Riley Securities | Buy |
| 2024-10-31 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-25 | ダウングレード | Jefferies | Buy → Hold |
| 2021-05-12 | 開始されました | BofA Securities | Buy |
| 2021-01-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-03-16 | ダウングレード | Oppenheimer | Perform → Underperform |
| 2020-03-12 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-08-01 | アップグレード | Citigroup | Neutral → Buy |
| 2019-07-25 | ダウングレード | Stifel | Buy → Hold |
| 2018-12-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2018-12-04 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 繰り返されました | Jefferies | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-09-21 | 再開されました | Oppenheimer | Outperform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2017-09-14 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-06-27 | 再開されました | Piper Jaffray | Overweight |
| 2017-05-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-12 | 開始されました | Oppenheimer | Outperform |
| 2016-11-09 | 開始されました | Aegis Capital | Buy |
| 2016-10-06 | 再開されました | Jefferies | Buy |
すべてを表示
Vanda Pharmaceuticals Inc (VNDA) 最新ニュース
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - PR Newswire
Vanda Pharmaceuticals’ stock tumbles after $220M loss - The Business Journals
Vanda Pharmaceuticals Inc files for mixed shelf offering of up to $200 millionSEC filing - marketscreener.com
Why Did Vanda Pharmaceuticals Stock Slide 7% Pre-Market Today? - Stocktwits
Vanda Pharmaceuticals, The New York Islanders New Jersey Sponsor - Yahoo Sports Canada
Vanda declines on Q4 results, weak 2026 revenue guidance - MSN
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Inc Files For Mixed Shelf Offering Of Upto $200 MillionSEC Filing - TradingView
Vanda Pharmaceuticals Inc. SEC 10-K Report - TradingView
Vanda Pharmaceuticals (VNDA) Eyes Growth Amidst Strong Prescription Sales and Pipeline Expansion - GuruFocus
Vanda (VNDA) Q4 2025 Earnings Call Transcript - AOL.com
Vanda Pharmaceuticals Inc (NASDAQ:VNDA) Stock Plummets 9.8% After Mixed Q4 2025 Earnings Report - ChartMill
Earnings call transcript: Vanda Pharmaceuticals Misses Q4 2025 Expectations By Investing.com - Investing.com India
Vanda Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Vanda: Q4 Financial Results Overview - Bitget
Vanda Pharmaceuticals (VNDA) Projects Lower FY26 Revenue Than Ex - GuruFocus
Vanda Pharmaceuticals (NASDAQ:VNDA) Issues Quarterly Earnings Results, Beats Expectations By $0.99 EPS - MarketBeat
Vanda: Q4 Earnings Snapshot - marketscreener.com
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
Vanda Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Analyst Downgrade: Will Vanda Pharmaceuticals Inc outperform tech stocksJuly 2025 Volume & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - The Malaysian Reserve
Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Thursday - MarketBeat
ETF Watch: Is Vanda Pharmaceuticals Inc stock a good pick for beginnersJuly 2025 WrapUp & Community Shared Stock Ideas - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 23.3% in January - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Biggest stock movers Wednesday: Vanda Pharmaceuticals, Axsome Therapeutics and Cybin - MSN
Take Profit: Can Vanda Pharmaceuticals Inc ride the EV wavePrice Action & Low Volatility Stock Suggestions - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (VNDA): Investor Outlook Reveals 77% Potential Upside - DirectorsTalk Interviews
Can Bysanti Redefine Vanda's Commercial Portfolio? - RTTNews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - Chartmill
Earnings Report: Can Vanda Pharmaceuticals Inc ride the EV waveForecast Cut & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - marketscreener.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc.VNDA - FinancialContent
Vanda Stock Drop 10% Premarket After FDA Rejects Jet Lag Drug Application - MSN
Millennium Management LLC Reduces Stake in Vanda Pharmaceuticals Inc - GuruFocus
VNDA: Imminent launches and label expansions position the portfolio for major near-term growth - TradingView — Track All Markets
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation - marketscreener.com
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Down 52.3% in December - MarketBeat
Loss Report: How Vanda Pharmaceuticals Inc stock benefits from tech adoptionShort Setup & Weekly High Potential Alerts - Bộ Nội Vụ
Revenue Check: Why Vanda Pharmaceuticals Inc stock remains a top recommendationPortfolio Gains Summary & Fast Gain Stock Tips - Bộ Nội Vụ
Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Finviz
Retail Trends: Will Vanda Pharmaceuticals Inc stock attract more institutional investorsProfit Target & Technical Confirmation Trade Alerts - Bộ Nội Vụ
Aug Retail: Why Vanda Pharmaceuticals Inc stock remains a top recommendation2025 Technical Overview & Weekly Consistent Profit Watchlists - Bộ Nội Vụ
Published on: 2026-01-12 16:11:40 - Улправда
What sentiment indicators say about Vanda Pharmaceuticals Inc. stockMarket Sentiment Summary & Weekly High Potential Stock Alerts - Улправда
Published on: 2026-01-08 21:09:38 - ulpravda.ru
Vanda Pharmaceuticals Inc (VNDA) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):